1. Home
  2. SLXN vs TRNR Comparison

SLXN vs TRNR Comparison

Compare SLXN & TRNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • TRNR
  • Stock Information
  • Founded
  • SLXN 2008
  • TRNR 2017
  • Country
  • SLXN Israel
  • TRNR United States
  • Employees
  • SLXN N/A
  • TRNR N/A
  • Industry
  • SLXN
  • TRNR Consumer Electronics/Appliances
  • Sector
  • SLXN
  • TRNR Technology
  • Exchange
  • SLXN NYSE
  • TRNR Nasdaq
  • Market Cap
  • SLXN 6.9M
  • TRNR 6.8M
  • IPO Year
  • SLXN N/A
  • TRNR 2023
  • Fundamental
  • Price
  • SLXN $0.92
  • TRNR $0.94
  • Analyst Decision
  • SLXN Strong Buy
  • TRNR
  • Analyst Count
  • SLXN 1
  • TRNR 0
  • Target Price
  • SLXN $5.00
  • TRNR N/A
  • AVG Volume (30 Days)
  • SLXN 3.6M
  • TRNR 2.0M
  • Earning Date
  • SLXN 05-13-2025
  • TRNR 05-19-2025
  • Dividend Yield
  • SLXN N/A
  • TRNR N/A
  • EPS Growth
  • SLXN N/A
  • TRNR N/A
  • EPS
  • SLXN N/A
  • TRNR N/A
  • Revenue
  • SLXN N/A
  • TRNR $5,380,000.00
  • Revenue This Year
  • SLXN N/A
  • TRNR $355.02
  • Revenue Next Year
  • SLXN N/A
  • TRNR N/A
  • P/E Ratio
  • SLXN N/A
  • TRNR N/A
  • Revenue Growth
  • SLXN N/A
  • TRNR 459.25
  • 52 Week Low
  • SLXN $0.21
  • TRNR $0.62
  • 52 Week High
  • SLXN $13.56
  • TRNR $996.00
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • TRNR 55.51
  • Support Level
  • SLXN N/A
  • TRNR $0.56
  • Resistance Level
  • SLXN N/A
  • TRNR $1.08
  • Average True Range (ATR)
  • SLXN 0.00
  • TRNR 0.10
  • MACD
  • SLXN 0.00
  • TRNR 0.06
  • Stochastic Oscillator
  • SLXN 0.00
  • TRNR 72.29

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

Share on Social Networks: